Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.
Carella
A M
AM
Podestá
M
M
Pollicardo
N
N
Pungolino
E
E
Raffo
M R
MR
Ferrero
R
R
Bergamaschi
G
G
Rosti
V
V
Cazzola
M
M
Saglio
G
G
D000328:Adult; D015703:Antigens, CD / Q000276:immunology*; D018952:Antigens, CD34; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000502:physiology; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006684:HLA-DR Antigens / Q000276:immunology*; D006410:Hematopoiesis / Q000187:drug effects* / Q000276:immunology / Q000502:physiology*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D008297:Male; D008875:Middle Aged
D015703:Antigens, CD; D018952:Antigens, CD34; D006684:HLA-DR Antigens; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D015255:Idarubicin